Invitrogen™ Elotuzumab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541877	100 μg

Catalog No. PIMA541877 Supplier Invitrogen™ Supplier No. MA541877

Description

Human Recombinant Monoclonal Antibody

Endotoxin level <0.01EU/ g by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148. 1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U. S. Food and pharmaceutical Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

Specifications

• Antigen: Elotuzumab Humanized
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 1 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: BMS-901608; PDL063;HuLuc63
• Host Species: Human
• Immunogen: Human SLAMF7/CD319.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov